NVO Gets FDA Nod, GALT Down But Not Out, BIOC Gets A Boost, CUR Excited

Today's Daily Dose brings you news about Avastin getting full approval for the most aggressive form of brain cancer; FDA action date for Clovis' Rucaparib sNDA; InspireMD's 24-month follow-up results of CGuard; Biocept's patent; Neuralstem's phase II study results of NSI-189 in major depressive disorder; Galectin's NASH trial results and Novo Nordisk's FDA approval.

from RTT - Biotech http://ift.tt/2B4H3av
via IFTTT